Direct sequencing advantage Helicos offers true single molecule sequencing for DNA, cDNA, and direct RNA without amplification, presenting a compelling value proposition for researchers seeking bias-free, high-accuracy measurements and streamlined workflows to accelerate discovery.

Service commercialization Recent launch of a sequencing services program creates a potential entry point for clients who need access to Helicos technologies without capital investment, enabling upsell opportunities for ongoing service engagements and future instrument adoption.

Early market positioning As an early entrant with pioneering single-molecule sequencing capabilities, Helicos can target early-adopter labs and institutions looking to differentiate research portfolios, while leveraging press coverage of its pioneering status to open introductions to related biotech buyers.

Strategic partnerships Given a modest team and significant technical differentiation, there is potential to partner with larger vendors or CROs for co-developed workflows, bundled offerings, or white-label services to broaden reach and scale commercial adoption.

Financial leverage With substantial funding and mid-range revenue, opportunities exist to pursue enterprise customers and grant-driven projects, emphasizing total cost of ownership, reduced manipulation biases, and demonstrable ROI to justify expanded procurement budgets.